Gland Pharma

Gland Pharma, a pharmaceutical preparation manufacturing company headquartered in India, reported its climate-related data for several years.

For the reporting year 2025 (data submitted in 2026), Gland Pharma's Scope 1 emissions were approximately 13,920,000 kg CO2e, and Scope 2 emissions were about 80,824,000 kg CO2e. The total combined Scope 1 and 2 emissions for this period were approximately 94,744,000 kg CO2e.

In the reporting year 2025 (data submitted in 2026), for FY2024-25, Scope 1 emissions stood at approximately 15,736,000 kg CO2e, with Scope 2 emissions at approximately 81,154,000 kg CO2e. This resulted in combined Scope 1 and 2 emissions of roughly 96,890,000 kg CO2e.

For the reporting year 2024 (data submitted in 2025), Gland Pharma disclosed Scope 1 emissions of approximately 11,929,600 kg CO2e and Scope 2 emissions of approximately 80,669,600 kg CO2e. The combined Scope 1 and 2 emissions for this period amounted to approximately 92,599,200 kg CO2e.

In the reporting year 2023 (data submitted in 2025), Scope 1 emissions were approximately 12,579,300 kg CO2e, and Scope 2 emissions were approximately 78,475,200 kg CO2e. The total for Scope 1 and 2 emissions was approximately 91,054,500 kg CO2e.

Gland Pharma's reporting indicates that Scope 3 emissions data, specifically for purchased goods and services, was not yet available for these reporting years.

The company's climate commitments and reduction targets are not detailed in the provided information. However, Gland Pharma is identified as a current subsidiary, and its performance data is sourced from "Gland Pharma Limited" at cascade level 0.